DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">

Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. — Alliance for NanoHealth
Navigation
 
 
 
You are here: Home Research Publications Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.
Document Actions

J Halder, YG Lin, WM Merritt, WA Spannuth, AM Nick, T Honda, AA Kamat, LY Han, TJ Kim, C Lu, AM Tari, W Bornmann, A Fernandez, G Lopez-Berestein, and AK Sood (2007)

Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.

Cancer Res. 67(22):10976-83.

Focal adhesion kinase (FAK) overexpression is frequently found in ovarian and other cancers and is predictive of poor clinical outcome. In the current study, we characterized the biological and therapeutic effects of a novel FAK inhibitor, TAE226. Taxane-sensitive (SKOV3ip1 and HeyA8) and taxane-resistant (HeyA8-MDR) cell lines were used for in vitro and in vivo therapy experiments using TAE226 alone and in combination with docetaxel. Assessment of cytotoxicity, cell proliferation [proliferating cell nucl